The Initial Public Offering (IPO) of Sai Parenterals Limited has opened for subscription today, offering investors an opportunity to participate in a growing pharmaceutical formulations and CDMO business. With a price band of ₹372–392 per share and strong anchor investor participation, the ₹409-crore IPO is attracting significant market attention.
Sai Parenterals aims to raise approximately ₹409 crore through its public issue. The IPO opened on March 24, 2026, and will close on March 27, 2026.
The price band for the issue has been fixed at ₹372 to ₹392 per equity share. Investors can bid for a minimum lot size of 38 shares, making it accessible to retail investors while also appealing to institutional participants.
The IPO follows the book-building route, where investor demand determines the final price within the specified range.
The IPO consists of two major components:
Fresh issue of equity shares worth up to ₹285 crore
Offer for sale (OFS) of up to 31,57,880 shares by existing shareholders
The OFS portion includes shares sold by notable investors such as Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Ashish Maheshwari, and others.
As per regulatory guidelines, the allocation of shares is divided into three categories:
Up to 50% for Qualified Institutional Buyers (QIBs)
Minimum 15% for Non-Institutional Investors (NIIs)
Minimum 35% for Retail Individual Investors (RIIs)
This structured allocation ensures balanced participation across investor segments.
Ahead of the IPO opening, Sai Parenterals successfully raised ₹122 crore from anchor investors, reflecting strong institutional confidence.
The company allocated over 31 lakh equity shares at ₹392 per share to leading institutional investors, including:
Morgan Stanley (Asia Singapore arm)
Kotak Mahindra Life Insurance Company
Kotak Life Sciences Fund
India Emerging Funds Limited
Quant Mutual Fund
This robust anchor participation is often viewed as a positive signal for market sentiment.
The funds raised from the fresh issue will be primarily used to support the company’s growth and expansion strategies.
A significant portion of the proceeds will be directed toward strengthening the company’s global formulations segment. This includes enhancing manufacturing capabilities and expanding product offerings in regulated international markets.
The company also plans to invest in its Contract Development and Manufacturing Organisation (CDMO) segment, focusing on both injectable products and oral solid dosage forms.
These investments aim to position Sai Parenterals as a reliable partner for global pharmaceutical companies.
Sai Parenterals operates as a diversified pharmaceutical formulations company with capabilities spanning research, development, and manufacturing.
The company’s portfolio covers multiple therapeutic areas, including:
It manufactures products across various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenterals has strong expertise in sterile injectable manufacturing, especially for critical care and antibiotics.
Its product range includes dry powder injections, prefilled syringes, ampoules, and vials—segments that require high regulatory compliance and technical expertise.
The company has built a solid manufacturing base in India, with a focus on quality and scalability.
Sai Parenterals owns and operates five manufacturing units in India, four of which are located in Hyderabad, Telangana.
The company strengthened its infrastructure by acquiring two internationally accredited manufacturing units, which marked the beginning of its export journey in FY2023.
The company exports its products to several regulated and semi-regulated markets, including:
These international operations are supported through a network of distributors.
Through its Singapore-based subsidiary, Sai Parenterals Pte Limited, the company has entered into strategic agreements with global partners, including UK-based firms, to expand its footprint in international markets.
Sai Parenterals has demonstrated consistent growth in its financial performance over recent years.
The steady increase in revenue and profits highlights the company’s improving operational efficiency and market expansion.
The IPO is being managed by Arihant Capital Markets, which is acting as the book-running lead manager.
The registrar for the issue is Bigshare Services Private Limited, responsible for handling investor applications and allotment processes.
Sai Parenterals’ IPO presents an opportunity for investors to gain exposure to the pharmaceutical sector, particularly in the high-growth CDMO and injectable segments.
The company’s expanding global presence, strong anchor backing, and improving financials make it an attractive proposition. However, investors should also consider market conditions, valuation, and sector-specific risks before making investment decisions.
Conclusion
The opening of Sai Parenterals’ IPO marks an important milestone in the company’s growth journey. With a well-defined expansion strategy, strong institutional support, and a diversified product portfolio, the company is positioning itself for long-term growth.
As the IPO progresses, investor response will play a key role in determining its success in the primary market.